Research Article

Safety and Efficacy of Corneal Crosslinking Treatment in Children with Keratoconus

Volume: 18 Number: 1 April 28, 2021
EN TR

Safety and Efficacy of Corneal Crosslinking Treatment in Children with Keratoconus

Abstract

Background: To evaluate the safety and efficacy of corneal crosslinking (CXL) treatment in children with keratoconus. Materials and Methods:A total of 45 eyes of 34 children with progressive keratoconus were included in this study. CXL was performed according to the conventional method. Manifest refraction, uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA), corneal topography values, and endothelial cell density (ECD) were evaluated at baseline and 24-month follow-up. Results:The mean age of the patients was 14.6 ± 3.5 years. The mean spherical equivalent readings were statistically significantly decreased at 24 months (p=0.016). There was a significant improvement in the mean UDVA and CDVA at 24 months (p=0.002, p=0.006, respectively). The mean K1 and K2 were statistically significantly reduced at 24 months postoperatively (p=0.004, p=0.006, respectively). There was no significant alteration in ECD at any follow-up examination. No significant sight-threatening complications were observed. Conclusions: The CXL procedure seem to be safe and effective in stabilizing keratoconus progression in children within a follow-up of 24 months.

Keywords

References

  1. 1.Rabinowitz YS. Keratoconus. Surv Ophthalmol. 1998; 42(4):297-319.
  2. 2.El-Khoury S, Abdelmassih Y, Hamade A, Slim E, Cherfan CG, Chelala E, et al. Pediatric keratoconus in a tertiary referral center: incidence, presentation, risk factors, and treatment. J Refract Surg. 2016; 32(8):534-41.
  3. 3.Sabti S, Tappeiner C, Frueh BE. Corneal cross-linking in a 4-year-old child with keratoconus and Down syndrome. Cornea. 2015; 34(9):1157-60.
  4. 4.Vinciguerra P, Albe E, Frueh BE, Trazza S, Epstein D. Two-year corneal cross-linking results in patients younger than 18 years with documented progressive keratoconus. Am J Ophthalmol. 2012; 154(3):520-6.
  5. 5.Leoni-Mesplie S, Mortemousque B, Touboul D, Malet F, Praud D, Mesplie N, et al. Scalability and severity of keratoconus in children. Am J Ophthalmol. 2012; 154(1):56-62.
  6. 6.Wollensak G, Spoerl E, Seiler T. Riboflavin/ultraviolet-a-induced collagen crosslinking for the teratment of keratoconus. Am J Ophthalmol. 2003; 135(5):620-7.
  7. 7.O’Brart DP, Kwong TQ, Patel P, McDonald RJ, O’Brart NA. Long-term follow-up of riboflavin/ultraviolet A (370 nm) corneal collagen cross-linking to halt the progression of keratoconus. Br J Ophthalmol.2013; 97(4):433-7.
  8. 8.Ghanem RC, Santhiago MR, Berti T, Netto MV, Ghanem VC. Topographic, corneal wavefront and refractive outcomes 2 years after collgen crosslinking for progressive keratoconus. Cornea. 2014; 33(1):43-51.

Details

Primary Language

English

Subjects

Clinical Sciences

Journal Section

Research Article

Publication Date

April 28, 2021

Submission Date

February 22, 2021

Acceptance Date

March 15, 2021

Published in Issue

Year 2021 Volume: 18 Number: 1

Vancouver
1.Deniz Özarslan Özcan, Sait Coşkun Özcan. Safety and Efficacy of Corneal Crosslinking Treatment in Children with Keratoconus. Harran Üniversitesi Tıp Fakültesi Dergisi. 2021 Apr. 1;18(1):145-8. doi:10.35440/hutfd.885032

Articles published in this journal are licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (CC-BY-NC-SA 4.0).